Search Results - joel+moss

7 Results

Sort By:

Defensin-Based Therapeutics for the Treatment of Pulmonary Disease

Investigators at the National Heart, Lung and Blood Institute have developed modified defensins that are resistant to degradation, have improved characteristics compared to unmodified defensins, and are promising candidates for pulmonary disease therapeutics. Defensins are small cationic peptides that defend the lung against pathogenic microorganisms...

Published: 7/25/2024 | Inventor(s): Joel Moss

Keywords(s): ADP-ribose, ADP-ribose-arginine, ADP-RIBOSYLARGININE, ADP-ribosylation, AIRWAY, Arginines, ASTHMA, BBXXXX, cytotoxic, CYTOTOXICITY, DBXXXX, defensin, Defensins, DXXXXX, HNP-1, human neutrophil peptide 1, IB4XXX, IBXXXX, Inflammation, IXXXXX, neutrophil, Patent Category - Biotechnology, Pulmonary, PULMONARY FIBROSIS

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Therapeutics, TherapeuticArea > Pulmonology, Application > Diagnostics, Application > Research Materials

ARH3, a Therapeutic Target for Cancer, Ischemia, and Inflammation

ADP-ribosylation is important in many cellular processes, including DNA replication and repair, maintenance of genomic stability, telomere dynamics, cell differentiation and proliferation, and necrosis and apoptosis. Poly-ADP-ribose is important in a number of critical physiological processes such as DNA repair, cellular differentiation, and carcinogenesis....

Published: 7/25/2024 | Inventor(s): Joel Moss

Keywords(s): Activity, Alpha-NAD, Alpha-NADase, ARH3, CB6XXX, CBXXXX, Cell, CXXXXX, Enzyme, Hydrolase:, IB6XXX, IBXXXX, Ihe, IXXXXX, LEVELS, Maintenance, MAMMALIAN, MAY, PAR, PARG-like, Patent Category - Biotechnology, Poly-ADP-ribose, RELEVANT

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Vaccines, Application > Therapeutics, TherapeuticArea > Immunology, TherapeuticArea > Oncology, TherapeuticArea > Reproductive Health, Application > Diagnostics, Application > Research Materials

Anti-Proliferative Activity of an Unexpected mTOR Kinase Inhibitor

The second leading cause of death in the United States is cancer and more than one million Americans are diagnosed with cancer each year, with this number likely to increase as the population ages. There remains a need for effective therapeutics with improved safety profiles, and promising results have been obtained from targeting the phosphatidylinositol-3-kinase...

Published: 4/8/2024 | Inventor(s): Joel Moss, Arnold Kristof

Keywords(s): BBXXXX, CB7XXX, CBXXXX, CXXXXX, IB3XXX, IBXXXX, IXXXXX

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Research Materials, Application > Therapeutics, Application > Diagnostics, TherapeuticArea > Immunology, TherapeuticArea > Oncology

Factors That Bind Intestinal Toxins

This invention discloses and covers polyphenolic compounds that will bind bacterial toxins, methods for the treatment of such infections, specifically Stx-1 toxins from STEC strains of E. coli. Bacterial infections not only cause disease by their presence but also upon the release of toxins. The common enteric bacteria, E. coli O157:H7 releases...

Published: 4/8/2024 | Inventor(s): Joel Moss, Masatoshi Noda

Keywords(s): DA3XXX, DAXXXX, DXXXXX, IB3XXX, IBXXXX, IXXXXX

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, Application > Research Materials, Application > Diagnostics

Tryptophan as a Functional Replacement for ADP-ribose-arginine in Recombinant Proteins

Bacterial toxins such as cholera toxin and diphtheria toxin catalyze the ADP-ribosylation of important cellular target proteins in their human hosts, thereby, as in the case of cholera toxin, irreversibly activating adenylyl cyclase. In this reaction, the toxin transfers the ADP-ribose moiety of Nicotinamide Adenine Dinucleotide (NAD) to an acceptor...

Published: 7/25/2024 | Inventor(s): Joel Moss

Keywords(s): cholera, DB3XXX, DBXXXX, DIPHTHERIA, DXXXXX

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Therapeutics

Modified Defensins and Their Use

The ubiquitous use of antibiotics has resulted in the selection of bacteria that are relatively resistant to these drugs. Furthermore, few drugs are effective against viral and fungal microorganisms. There is therefore a continuing need to identify novel agents that reduce or inhibit the growth of such microorganisms, or to identify ways of modifying...

Published: 7/25/2024 | Inventor(s): Joel Moss

Keywords(s): DB3XXX, DBXXXX, DXXXXX, IB3XXX, IB4XXX, IBXXXX, IXXXXX

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Immunology, TherapeuticArea > Pulmonology, Application > Therapeutics, Application > Research Materials, Application > Diagnostics, TherapeuticArea > Infectious Disease

Clones Encoding Mammalian ADP-Ribosylarginine Hydrolases

ADP-ribosylation of arginine residues in proteins may be involved in cell adhesion and is crucial for the action of cholera toxin and E. coli heat-labile enterotoxin, agents involved in the pathogenesis of cholera and traveller's diarrhoea, respectively. ADP-ribosylation is reversed by ADP-ribosylarginine hydrolases, which cleave the ADP-ribose-arginine...

Published: 4/8/2024 | Inventor(s): Joel Moss, Sally Stanley, Maria Nightingale, James Murtagh, Lucia Monaco, Tatsuyuki Takada

Keywords(s): cholera, Cholera (Vibrio cholerae), DA3XXX, DAXXXX, DB3XXX, DBXXXX, DXXXXX

Category(s): Collaboration Sought > Licensing, Application > Diagnostics, TherapeuticArea > Infectious Disease, Application > Therapeutics